Downstream processing of viral vectors and vaccines

Gene Therapy

Volumn 12, Issue , 2005, Pages S103-S110

  Morenweiser, R ^a  

^a GE HEALTHCARE   (Germany)

Author keywords

Chromatography; Downstream processing; Tangential flow filtration; Viral vaccine; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; HEPATITIS VACCINE; INFLUENZA VACCINE; LENTIVIRUS VECTOR; NAKED DNA; PARVOVIRUS VECTOR; PLASMID DNA; RABIES VACCINE; RETROVIRUS VECTOR; VIRUS VACCINE; VIRUS VECTOR;

CELL CULTURE; CONFERENCE PAPER; DOWNSTREAM PROCESSING; DRUG PURIFICATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEPATITIS; HEPATITIS VIRUS; INFLUENZA; INFLUENZA VIRUS; LIQUID CHROMATOGRAPHY; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; RABIES; RABIES VIRUS; SUCROSE DENSITY GRADIENT CENTRIFUGATION; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BIOTECHNOLOGY; CELL LINE; CHROMATOGRAPHY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; SAFETY; VIRAL VACCINES; VIRUS CULTIVATION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; INFLUENZA VIRUS; LENTIVIRUS; MAMMALIA; PARVOVIRUS; RABIES VIRUS;

EID: 27544467262     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302624     Document Type: Article

References (51)

1. Blaese R et al. T lymphocyte-directed gene therapy for ADA deficiency SCID: initial trial results after 4 years. Science 1995; 270: 475-480.
2. The Journal of Gene Medicine, Gene Therapy Clinical Trials, Charts and Tables, Vectors, 2005; http:ll82.182.180.141ltrialsl FMPro?-db =Trials.FP5&-format =vectors.html&-lay=Vectors&-findAll.
3. Lyddiatt A, O'Sullivan D. Biochemical recovery and purification of gene therapy vectors. Curr Opin Biotechnol 1998; 9: 177-185.
4. Wu N, Ataai M. Production of viral vectors for gene therapy applications. Curr Opin Biotechnol 2000; 11: 205-208.
5. Braas G, Searle P, Slater N, Lyddiatt A. Strategies for the isolation and purification of retroviral vectors for gene therapy. Bioseparation 1996; 6: 211-228.
6. Guilherme N, Monteiro G, Prozeres D, Cabral J. Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications. TIBTECH 2000; 18: 380-388.
7. Zolotukhin S et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.
8. Saha K, Lin Y-C, Wong P. A single method for obtaining highly viable virus from culture supernatant. J Virol Methods 1994; 46: 349-352.
9. Aboud M, Wolfson M, Hassan Y, Huleihel M. Rapid purification of extracellular and intracellular Moloney murine leukemia virus. Arch Virol 1982; 71: 185-195.
10. Morling F, Russell S. Enhanced transduction efficiency of retroviral vectors coprecipitated with calcium phosphate. Gene Therapy 1995; 2: 504-508.
11. Andreadis S et al. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog 1999; 15: 1-11.
12. Hammar L, Gilljam G. Extraction of HIV-1 in aqueous two- phase systems to obtain a high yield of gp120. AIDS Res Hum Retroviruses 1990; 6: 1379-1388.
13. Morenweiser R. Amersham Biosciences. Downstream 2004; 37: 20-21.
14. McGrath M, Witte O, Pincus T, Weissman I. Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity. J Virol 1978; 25: 923-927.
15. Ljunglof A, Bergvall P, Bhikhabhai R, Hjorth R. Direct visualization of plasmid DNA in individual chromatography adsorbent particles by confocal scanning laser microscopy. J Chromatogr A 1999; 844: 129-135.
16. Martin M, El Azher M, Vasseur M. Ionic strength- and temperature-induced KCa shifts in the uncoating reaction of rotavirus strains RF and SA11: correlation with membrane permeabilization. J Virol 2002; 76: 552-559.
17. Specht R et al. Densonucleosis virus purification by ion exchange membranes. Biotechnol Bioeng 2004; 88: 465-473.
18. Huyghe B et al. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 1995; 6: 1403-1416.
19. Herzer S, Wegmann T, Beckett P. Isoelectric titration curves of viral particles as an evaluation tool for ion exchange chromatography. Life Sci News 2003; 13: 16-18.
20. Valdes R et al. Hepatitis B surface antigen immunopurification using a plant-derived specific antibody produced in large scale. Biochim Biophys Res Commun 2003; 310: 742-747.
21. Grimm D, Kern A, Rittner K, Kleinschmidt J. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
22. Walther W, Stein U. Viral vectors for gene transfer. Drugs 2000; 60: 249-271.
23. Higashikawa F, Chang L. Kinetic analyses of stability of simple and complex retroviral vectors. Virology 2001; 280: 124-133.
24. Darling D et al. Low-speed centrifugation of retroviral vectors absorbed to a particulate substrate: a highly effective means of enhancing retroviral titer. Gene Therapy 2000; 7: 914-923.
25. Kuiper M, Sanches R, Walford J, Slater N. Purification of a functional gene therapy vector derived from Moloney murine leukemia virus using membrane filtration and ceramic hydroxyapatite chromatography. Biotechnol Bioeng 2002; 80: 445-453.
26. Baekelandt V et al. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Therapy 2003; 10: 1933-1940.
27. Zhang B et al. A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors. Gene Therapy 2001; 8: 1745-1751.
28. Reiser J. Production and concentration of pseudotyped HIV-1- based gene transfer vectors. Gene Therapy 2000; 7: 910-913.
29. Richieri S et al. Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography. Vaccine 1998; 16: 119-129.
30. Bondoc L, Fitzpatrick S. Size distribution analysis of recombinant adenovirus using disc centrifugation. J Ind Microbiol Biotechnol 1998; 20: 317-322.
31. Green A et al. A new scalable method for the purification of recombinant adenovirus vectors. Hum Gene Ther 2002; 3: 1921-1934.
32. Kamen A, Henry O. Development and optimization of an adenovirus production process. J Gene Med 2004; 6: 184-192.
33. Smith A. Viral vectors in gene therapy. Annu Rev Microbiol 1995; 49: 807-838.
34. Blanche F et al. An improved anion-exchange HPLC method for the detection and purification of adenoviral particles. Gene Therapy 2000; 7: 1055-1062.
35. Smith R, Ding C, Kotin R. Serum-free production and column purification of adeno-associated virus type 5. J Virol Meth 2003; 114: 115-124.
36. Davidoff A et al. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J Virol Methods 2004; 121: 209-215.
37. O'Riordan C, Lachapelle A, Vincent K, Wadsworth S. Scaleable chromatographic purification process for recombinant adeno- associated virus (rAAV). Gene Med 2000; 2: 444-454.
38. Summerford C, Samulski R. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med 1999; 5: 587-588.
39. Summerford C, Samulski R. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 vectors. J Virol 1998; 72: 1438-1445.
40. Auricchio A, O'Connor E, Hildinger M, Wilson J. A single-step affinity column for purification of serotype-5 based adeno- associated viral vectors. Mol Ther 2001; 4: 372-374.
41. Clark K, Liu M, McGrath J, Johnson P. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild type viruses. Hum Gene Ther 1999; 10: 1031-1039.
42. Brument N et al. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. Mol Ther 2002; 6: 678-686.
43. Blouin V et al. Improving rAAV production and purification: towards the definition of a scaleable process. J Gene Med 2004; 6: 223-228.
44. Siegel J. Gene Therapy: Is There Oversight for Patient Safety?. Testimony before the Senate Committee on Health, Education, Labor and Pensions, Subcommittee on Public Health, February 2, 2000.
45. The European Agency for the Evaluation of Medicinal Products, Note for Guidance on Quality, Preclinical and clinical aspects of gene transfer medicinal products, 9CPMPlBWPl3088l99, London, April 24, 2001, pp 1-33, http:llwww.emea.eu.intl pdfslhumanlbwpl308899en.pdf.
46. Food and Drug Administration [Docket No. 2004D-0465], Draft Guidance for Food and Drug Administration Review Staff and Sponsors: Content and Review of Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications, November 1, 2004, pp 1-4, http:llwww.fda.govlohrmsldocketsl98frlcb0240.pdf.
47. Food and Drug Administration Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy, dated March 1998, http:llwww.fda.govlcberlgdlnslsomgene.pdf.
48. Food and Drug Administration Guidance for Industry: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products, dated November 1995, http:llwww.fda.govlcderlguidancelphase1.pdf.
49. Food and Drug Administration Draft Guidance for Reviewers: Instructions and Template for Chemistry, Manufacturing, and Control (CMC) Reviewers of Human Somatic Cell Therapy Investigational New Drug Applications (INDs), dated August 2003, http:llwww.fda.govlcberlgdlnslcmcsomcell.pdf.
50. Borellini F, Ostrove J. The transfer of technology from the laboratory to the clinic: in-process controls and final product testing. In: Meager A (ed). Gene Therapy Technologies, Applications and Regulations. John Wiley & Sons Ltd: New York, 1999, pp 359-373.
51. Su Z-Z et al. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci USA 2005; 102: 1059-1064.